Abstract
• A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage. • Controlled studies may highlight a potential preventive role of immunosuppressant in the development of Covid-19 severe forms • Despite the risk of infection in rheumatic and gastroenterological diseases a conclusive link with COV-19 remains questionable
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.